Neuralstem CEO, Richard Garr, featured in Wall Street JournalRegarding this week's FDA sessions on human trials: "The FDA is nervous. It's under tremendous pressure. They can't appear adversarial but they can't seem to be rolling over for industry, either" said Richard Garr, CEO of Neuralstem Inc... Mr. Garr said he is worried that if the hearings focus on unresolved safety problems in embryonic-stem-cell technology the FDA could decide to slow down the process..." Read the full article on the FDA human trials hearings. Neuralstem CEO, Richard Garr, featured in CNNmoney.com In an article April 9, 2008, CNNMoney.com interviews Richard Garr, CEO of Neuralstem, about upcoming FDA meetings about human testing for stem cell therapies. See the article by Aaron Smith in CNNMoney.com. Microsoft Money contributing writer Michael Brush recommends Neuralstem for model portfolioPlease read the full article: 5 hot stocks at Big Mac prices. Neuralstem to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference November 5, 2007 Neuralstem, Inc. (Amex: CUR - News) today announced that Richard Garr, President & Chief Executive Officer of Neuralstem, will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York on Monday, November 5, 2007 at 10:55a.m., eastern. You can access the live webcast at: http://www.wsw.com/webcast/rrshq12/nrls.ob An archive will be available after the presentation. Rubicon Global Research Buy-Side Investment AnalysisOctober 9, 2007 - Investment Thesis/ Summary Conclusion: Neuralstem, Inc. is a biopharmaceutical company with a robust and diverse development pipeline derived from its novel and patent protected human neural stem cell (hNSC) technology. The Company’s research and development efforts target the treatment of debilitating central nervous system (CNS) disorders for which no effective treatments exists. Full article ... Attacking Lou Gehrig’s Disease from all AnglesMay 23, 2007 - Attacking Lou Gehrig’s Disease from all Angles: UC San Diego stem cell researcher will participate in major U of Michigan research effort The potential use of stem cells to treat the paralyzing disease amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, will be the focus of a new research project at the University of California, San Diego (UCSD) School of Medicine in partnership with the University of Michigan. full article... StemCells Agrees to Stay in Patent SuitThursday June 28, 11:51 am ET - StemCells Agrees to Stay in Lawsuit Against Neuralstem Over Disputed Patents PALO ALTO, Calif. (AP) -- Biotechnology company StemCells Inc. said Thursday it has agreed to a stay in its patent-dispute lawsuit against Neuralstem Inc. while the U.S. Patent and Trademark Office re-examines the patents in question. full article...
Neuralstem reports spinal cord damage resultsWashington Business Journal - 8:44 AM EDT Wednesday, May 30, 2007by Jeff ClabaughStaff Reporter The Rockville-based company, founded by a former National Institutes of Health scientist, reported in the online journal Neuroscience that three rats paralyzed by a specific spinal cord injury returned to near normal ambulatory function six weeks after having stems cells grafted to their spinal cords. Three others showed significant improvement after two months. full article... Neuralstem's cells reverse paralysis
UPI - Published: May 30, 2007 at 11:10 AM ROCKVILLE, Md., May 30 (UPI) -- U.S. firm Neuralstem said Wednesday its human spinal stem cells reversed paralysis in a rat model of a spinal disorder. full article... Richard Garr on TheStreet.com
Richard Garr interviewed by Gregg Greenberg about the Business of Stem Cells on May 22, 2007. Click here to view the interview. Richard Garr at the Wall Street Analyst Forum
Richard Garr briefs The Wall Street Analyst Forum 18th Annual Analyst Conference 5/22/2007. Cick here to view the presentation. Neuralstem receives buy recommendationOn March 19th, 2007 ChangeWave MicroCap Investor, an advisory service published by ChangeWave Research issued a “buy” Recommendation on Neuralstem shares. MORNING NOTES, Michael A. Berry, Ph.D.Friday February 16, 2007
We’ve had a few days of Fed Chief Bernanke’s testimony in front of the “new” Congress for the semi-annual report. By all reports the House Financial Services Committee has been more than accommodating to him.
Still a confusing inflation theme seeps forth. Dr. Bernanke said, “We’ve seen some very strong consumer spending numbers and we’ve seen some strong income growth, which suggests that the economy may be stronger than we think … View the full article MORNING NOTES, Michael A. Berry, Ph.D.Friday January 12, 2007 Neuralstem (NRLS OTC BB), a company I have classified as a discovery company,
announced that it has executed an exclusive license of its proprietary stem cell line to
Biomedical Research Models, Inc. for the development of Neuralstem compounds to treat
the cognitive and neurological impacts of diabetes. The license covers a library of
Neuralstem patent-pending compounds, discovered using Neuralstem’s patented human
neural stem cells. The company said that the compounds, when orally administered, have been shown in adult mice to recruit and stimulate the body’s own stem cells to
form new neurons in the brain, and may be useful in healing and protecting injured
brain areas. Biomedical Research Models, Inc., is focused on developing novel drug
therapies for the treatment of diabetes. Neuralstem also recently received a $500,000
grant from the National Institute of Health to study compounds to treat depression. It is very early in the Discovery cycle for investors in NRLS. However it appears that the
company has a platform that produces regionally specific, physiologically relevant
human nerve cells in large quantities. The company retains the rights to all indications
except for the diabetes. Neuralstem CEO speaks at Paulson Investment's Westergaard SmallCap Conference, November 6, 2006Click here to view the webcast.
StemCells Accused by Neuralstem of Misusing Patents (Update2)2006-10-31 16:45 (New York) By Susan Decker and Rob Waters Oct. 31 (Bloomberg) -- StemCells Inc. was accused by Neuralstem Inc. of misusing patents in an effort to monopolize the use of stem-cell technology in research on damage to the nervous system. Neuralstem, in papers filed yesterday in U.S. District Court in Greenbelt, Maryland, claimed StemCells also used ``sham litigation'' to control the market. The filing was in response to an infringement suit StemCells brought against Neuralstem in July. Neuralstem has asked U.S. District Judge Alexander Williams Jr. to dismiss the case. ``StemCells' initiation of this lawsuit constitutes an intentional attempt to monopolize the relevant neural stem cell market, and a dangerous probability exists that StemCells will succeed in this scheme,'' Neuralstem said in the filing. View the full article. Stem cells delay paralyzing diseaseMon Oct 16, 2006 3:08 PM ET By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - Human fetal stem cells can graft onto the spines of rats and delay some of the paralyzing symptoms of motor neuron disease, commonly known as Lou Gehrig's disease, U.S. researchers reported on Monday. The new cells were resistant to the disease, also known as amyotrophic lateral sclerosis or ALS, the researchers said. A company associated with the researchers is incubating batches of the human cells, taken from an aborted fetus, and hopes to market them as a treatment for several sorts of paralyzing conditions. View the fu ll article on Reuters.com. Human Stem Cells Help Rats to Fend Off Lou Gehrig's Disease
By Rob Waters Oct. 15 (Bloomberg) -- Neural stem cells transplanted into the spinal cords of rats from a human fetus slowed onset of a form of Lou Gehrig's disease, a condition that attacks the nerve circuits that control movement. Researchers placed the cells in rats genetically engineered to develop a form of the disease, also know as amyotrophic lateral sclerosis or ALS. The rodents with the cells were slower to show symptoms such as weight loss and diminished strength, and lived about 11 days longer over a 30-month life span. View the full article on Bloomberg.com. NeuralStem CEO, I.R. Garr Quoted in Baltimore SunAugust 4, 2006 - In an article in the Baltimore Sun, it was announced that Osiris Therapeutics, Inc. is the third Maryland biotechnology company to go public this year. The company raised about $38.5M. According to the article by Tricia Bishop, "Neuralstem Inc. is another Maryland stem cell company hoping to take that route this year. 'Ultimately, we're going to need a lot of resources,' Chief Executive Officer I. Richard Garr said in an earlier interview. "There comes a point where you can only get those resources from a public market." Registered users of the Baltimore Sun website can view the full article by clicking here (requires free registration to BaltimoreSun.com). StemCells ACCUSES Neuralstem OF INFRINGING STEM-CELL PATENTS
July 25, 2006 (Bloomberg) -- StemCells Inc., which uses stem cells to research treatments for damage to the nervous system, liver and pancreas, sued Neuralstem Inc. to stop the development of rival products. StemCells said it owns the basic technology for the use of neural stem cells, derived from the brain and spinal cord, and Neuralstem lacks a license, according to the lawsuit filed yesterday in Greenbelt, Maryland. The companies are the only ones with patented technology for the use of neural stem cells, Neuralstem Chief Executive Officer Richard Garr said. StemCells, based in Palo Alto, California, failed to persuade the U.S. Patent and Trademark Office to withdraw a Neuralstem patent. (more)
Download the publication document here.
| 
November 27, 2009 - Atlanta Business Chronicle - by Urvaksh Karkaria Staff Writer - Emory University will be the site of the first U.S. clinical trail that focuses on using stem cells to slow the progression of adults with Lou Gehrig’s disease.
Sept 21, 2009 (Reuters) - Neuralstem Inc (CUR.A: Quote, Profile, Research, Stock Buzz) said U.S. health regulators allowed the stem-cell research company to start an early-stage human trial of its spinal cord stem cells in Lou Gehrig's disease, a fatal neuromuscular condition. Shares of the company soared 63 percent to $3.05 in premarket trade. They closed at $1.87 Friday on the American Stock Exchange. (
Tuesday, September 22, 2009, The Detroit News, U-M to oversee clinical trial on 12 patients in Atlanta, Kim Kozlowski - A leading neurologist at the University of Michigan will oversee a federally approved clinical trial involving stem cells that researchers hope will hold a key to slowing the progression of Lou Gehrig's disease. New cases of the fatal, neurodegenerative disease known as amyotrophic lateral sclerosis (ALS) are diagnosed in 5,600 Americans annually. Patients with the disease, which ultimately leads to paralysis and the inability to speak or move, have a three- to five-year life expectancy. (
September 22, 2009 (The Great Beyond), Monya Baker, The Maryland company NeuralStem has the U.S. Food and Drug Administration’s permission to test its spinal cord stem cells in twelve patients with amyotrophic lateral sclerosis. The approval comes a month after the FDA placed Geron’s planned clinical trial on hold for a second time. NeuralStem’s trial had also previously been placed on hold by the FDA in February before receiving the go-ahead in September.. (
Talk with University of Michigan neurology Professor Dr. Eva Feldman (
Monday, June 8th, 2009 - New research by the Maryland biotech firm, Neuralstem, has earned them a patent for chemicals that that can make the brain grow new brain cells. We should note that growing more brain cells will not make you any smarter...but it could offer treatments for people suffering from a stroke, or Alzheimer's disease, or major depression. To find out more, we talked to Richard Garr, he's the President and CEO of Neuralstem.
President Obama's decision to allow federal tax dollars to be used with embryonic stem cell research does more than reverse his predecessor's policies and fulfill a long-standing campaign promise. It also reopens the debate about how well science and politics can, or should, mix. On Monday, Obama signed an executive order allowing research on more stem cell lines than the Bush administration had permitted in its political compromise eight years ago... 
BALTIMORE Radio WYPR - Maryland Morning with Sheila Kast - News from Washington announcing a lift on the ban on funding for embryonic stem cell research is expected today. Meanwhile in Annapolis, a bill is being considered that will change the Maryland stem cell commission.
WASHINGTON - Shares of companies developing stem cell therapies surged Friday evening on word that President Obama on Monday is expected to overturn restrictions that have choked funding for academic stem cell research. 
WASHINGTON The FDA is giving a thumbs-up to the first human trial involving embryonic stem cells. The study, which will examine the safety of this treatment in people with spinal cord injuries, comes in advance of a widely-anticipated shift in U.S. policy on embryonic stem cells. Join Kojo as we explore the intersection of bioethics and stem cell research 
WASHINGTON Perhaps no sector has more to gain under the Obama administration than the nation's fledgling stem cell companies, which have long bemoaned a Bush policy that limits funding to embryonic stem cell research. Barack Obama has pledged to overturn that 2001 policy, which bans government funds for research that involves harvesting new stem cells. President Bush and a minority of Americans say the process is immoral because it destroys human embryos. 
A sea change in stem cell industry investment is coming, says Richard Garr. The CEO of Gaithersburg-based Neuralstem happened to be in New York last week, pitching his company to prospective investors, when a member of President-elect Barack Obama's transition team said one of Obama's first priorities as president will be to lift the federal ban on funding embryonic stem cell research imposed by President Bush nearly eight years ago. 
ROCKVILLE, Md., Nov. 18 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today that it has entered into a collaboration with Professor Guido Nikkah Ph.D, of Albert-Ludwigs-University in Freiburg, Germany, to advance development of Neuralstem's human neural stem cell therapies. The collaboration with Professor Nikkah will focus on Huntington's disease...